Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Weihai Huazhong Pharmaceutical is a leading Chinese manufacturer of active pharmaceutical ingredients (APIs), primarily focusing on xanthine derivatives. The company is one of the world's largest producers of caffeine anhydrous, theophylline, and aminophylline, serving both the global pharmaceutical and food and beverage sectors. As a key subsidiary of Shandong Xinhua Pharmaceutical, it operates sophisticated manufacturing facilities that meet international quality standards, including GMP, CEP, and US FDA requirements. The company's strategic location in Weihai allows it to efficiently export products to over 60 countries and regions. In addition to bulk API production, Weihai Huazhong offers contract manufacturing and development services for small molecule therapeutics. Its large-scale production capacity and commitment to quality have established it as a critical supplier in the global healthcare supply chain.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Weihai Huazhong Pharmaceuticals.